Apogee Therapeutics, Inc. APGE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s additional paid-in capital?
- Apogee Therapeutics, Inc. (APGE) reported additional paid-in capital of $1.89B in Q1 2026.
- How has Apogee Therapeutics, Inc.'s additional paid-in capital changed year-over-year?
- Apogee Therapeutics, Inc.'s additional paid-in capital increased by 83.1% year-over-year, from $1.03B to $1.89B.
- What is the long-term trend for Apogee Therapeutics, Inc.'s additional paid-in capital?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s additional paid-in capital has grown at a 70.6% compound annual growth rate (CAGR), from $503.35M to $1.46B.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.